SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 4. P. 71-80

REVIEW

A.A. Danilenko, S.V. Shakhtarina

Radiation Therapy of Hodgkin’s Lymphoma: From “Radical Program” of Treatment to Modern Technologies

A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

First significant achievements in treatment of Hodgkin’s lymphoma patients were obtained due to radiation therapy. Compound chemotherapy introduced later also yielded considerable results. Combined modality of these two methods produced the most effective treatment. Radiation therapy gradually underwent changes as a result of technical innovations and improving concept of optimal treatment volumes and doses. The review presents literature data on the history of radiation therapy for Hodgkin’s lymphoma patients used alone, and in combination with chemotherapy.

Key words: Hodgkin’s lymphoma, radiotherapy, chemo-radiotherapy

REFERENCES

  1. Lukes R.J., Butler J.J. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966. Vol. 26. No. 6. P. 1063-1083.
  2. Kaplan H.S., Rosenberg S.A. The management of the Hodgkin’s disease. Cancer, 1975. Vol. 36. No. 2. P. 796-803.
  3. Glatstein E., Guernsey J.M., Rosenberg S A. et al. The value of laparotomy and splenectomy in the staging of Hodgkin’s disease. Cancer, 1969. Vol. 24. No. 4. P. 709-718.
  4. Carbone P.P., Kplan H.S., Musshoff K. et al. Report of the Committee on Hodgkin’s disease staging classification. Cancer Res. 1971. Vol. 31. No. 11. P. 1860-1961.
  5. Lister T.A., Crowther D., Sutcliffe S.B. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswold’s meeting. J. Clin. Oncol. 1989. Vol. 7. No. 11. P. 1630-1636.
  6. Meignan M., Gallarnini A., Itti E. et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk. Lymphoma, 2012. Vol. 53. No. 10. P. 1876-1881.
  7. Kaplan H.S. Long-term results of palliative and radical radiotherapy of Hodgkin’s disease. Cancer Res. 1966. Vol. 26. No. 1. P. 1250-1252.
  8. Baisogolov G.D., Khmelevskaya Z.I. Luchevaya terapiya limfogranulematoza po radikal'noi programme (metodicheskie rekomendatsii). Minzdrav SSSR, Akademiya med. nauk SSSR. 1972. 45 p. (In Russ.).
  9. Shakhtarina S.V., Pavlov V.V., Danilenko A.A., Afanasova N.V. Lechenie bol'nykh limfomoi Khodzhkina s lokal'nymi stadiyami I, II, IE, IIE: opyt Meditsinskogo radiologicheskogo nauchnogo tsentra. Klinicheskaya onkogematologiya, 2007. No. 4. P. 36-46. (In Russ.).
  10. Duhmke E., Franklin J., Pfreundschuh M. et al. Lowdose radiation is sufficient for the non involved extended field treatment in vavorable early stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J. Clin. Oncol. 2001. Vol. 19. No. 11. P. 2905-2914.
  11. Huguley C.M., Durant J.R., Moores R.R., at al. A comparison of nitrogen mustard, vincristine, procarbasine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin’s disease. Cancer. 1975. Vol. 36. No. 4. P. 1227-1240.
  12. Canellos G.P., Rosenberg S.A., Friedberg J.W. et al. Treatment of Hodgkin’s lymphoma: A 50-year perspective. J. Clin. Oncol. 2014. Vol. 32. No. 3. P. 163-168.
  13. Bonadonna G., Zucali R., Monfardini S. et al. Combunation chemotherapy of Hodgkin’s diseasewith adriamycin, vinblastine, and imidazole carboxiamide versus MOPP. Cancer. 1975. Vol. 36. No. 1. P. 252-259.
  14. Canellos G.P., Niedzwiecki D., Johnston J.L. Longterm follow up of survival in Hodgkin’s lymphoma. N. Engl. J. Med. 2009. Vol. 361. No. 24. P. 2390-2391.
  15. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N. Engl. J. Med. 1998. Vol. 339. No. 21. P. 1506-1514.
  16. Diehl V., Franklin J., Hasenclever D. et al. BEACOPP: a new regimen for advanced Hodgkin’s disease - German Hodgkin’s Lymphoma Study Group. Ann. Oncol. 1998. Vol. 9. Suppl. 5. P. 67-71.
  17. Horning S.G., Hoppe R.T., Breslin S. et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J. Clin. Oncol. 2002. Vol. 20. No. 3. P. 630-637.
  18. Kelly K.M., Sposto R., Hutchinson R. et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood. 2011. Vol. 117. No. 9. P. 2596-2603.
  19. Fuller L.M., Hagemeister F.B., North L.B. et al. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage I through IIB Hodgkin’s disease: preliminary results. Int. J. Radiat. Biol. Phys. 1988. Vol. 14. No. 4. P. 683-692.
  20. Longo D.L., Glatstein E., Duffey P.L. et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J. Clin. Oncol. 1991. Vol. 9. No. 6. P. 906-917.
  21. Shakhtarina S.V. Luchevoe, polikhimio-luchevoe, lekarstvennoe lechenie pervichnykh form limfogranulematoza I-IV stadii. Obninsk. Diss. dokt. med. nauk. 1995. 413 p. (In Russ.).
  22. Lister T.A. Treatment of stage IIIa Hodgkin’s disease: Long follow-up perspective. J. Clin. Oncol. 2008. Vol. 26. No. 2. P. 5144-5146.
  23. Shakhtarina S.V. Kombinirovannoe (luchevoe i lekarstvennoe) lechenie bol'nykh limfogranulematozom I-II stadii. Obninsk, diss. kand. med. nauk. 1985. 175 p. (In Russ.).
  24. Straus D.J., Portlock C.S., Qin G. et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by r5adiation therapy (RT) versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin’s disease. Blood. 2004. Vol. 104. No. 12. P. 3483-3489.
  25. Campbell B.A., Hornby C., Cunninghame J. et al. Minimising critical organ irradiation in limited stage Hodgkin’s lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann. Oncol. 2012. Vol. 23. No. 5. P. 1259-1266.
  26. Isaev I.G. Luchevaya terapiya v kombinirovannom lechenii bol'nykh limfogranulematozom IIIB-IV stadii. Obninsk. Diss. kand. med. nauk. 1981. 182 p. (In Russ.).
  27. Zittoun R., Audebert A., Hoerni B. et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J. Clin. Oncol. 1985. Vol. 3. No. 2. P. 207-214.
  28. Datsenko P.V. Metodika luchevoi terapii s poetapnym zonal'nym sokrashcheniem polei. V kn.: «Limfoma Khodzhkina». OOO «TID «Russkoe slovo-RS». 2009. P. 145-148. (In Russ.).
  29. Shakhtarina S.V., Pavlov V.V., Danilenko A.A., Lashkova O.E. Treatment of Hodgkin’s disease patients with radio-chemotherapy using reduced (20-30 Gy) total tumor doses. Abstracts for the 6th Symp. On Hodgkin’s lymphoma. Cologne, Germany. 18-21 Sept. 2004. Haematol. 2004. Vol. 73. Suppl. 65. P. 39-40.
  30. Shakhtarina S.V., Danilenko A.A., Pavlov V.V., Dvinskikh N.Yu. Kombinirovannoe lechenie pervichnykh bol'nykh limfomoi Khodzhkina I-II stadii s primeneniem luchevoi terapii v umen'shennykh summarnykh ochagovykh dozakh (20-30 Gr) i khimioterapii po skhemam SORR, ABVD, BEACOPP-21. Mat-ly nauchno-prakt. konf. «Aktual'nye voprosy diagnostiki i lecheniya limfomy Khodzhkina (po rezul'tatam lechebnykh programm 1998-2008 g.)». 15-17 Apr. 2010. Obninsk. 64 p. (In Russ.).
  31. Minimal'nye klinicheskie rekomendatsii Evropeiskogo obshchestva meditsinskoi onkologii (ESMO). Moscow, publ. gruppa RONTs im. N.N. Blokhina RAMN. 2010. 433 p. (In Russ.).
  32. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. Under the guidance of I.V. Poddubnoi, V.G. Savchenko. Moscow: Media Medika, 2013. 102 p. (In Russ.).
  33. Meyer R.M., Gospodarovicz M.K., Connors J.M. et al. ABVD alone versus radiation-based therapy in limitedstage Hodgkin’s lymphoma. N. Engl. J. Med. 2012. Vol. 366. No. 5. P. 399-408.
  34. Bonadonna G., Bonfante V., Viviani S. et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J. Clin. Oncol. 2004. Vol. 22. No. 14. P. 2835-2841.
  35. Ferme C., Eghbali H., Meerw3aldt J.H. et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N. Engl. J. Med. 2007. Vol. 357. No. 19. P. 1916-1927.
  36. Franklin J., Pluetshow A., Paus M.D. et al. Second malignancy risk associated with treatment for Hodgkin’s lymphoma: meta-analysis of the randomized trials. Ann. Oncol. 2006. Vol. 17. No. 12. P. 1749-1760.
  37. Engert A., Plutschow A., Eich H.T. et al. Reduced treatment intensity in patients with early stage Hodgkin’s lymphoma. N. Engl. J. Med. 2010. Vol. 363. No. 7. P. 640-652.
  38. Eich H.T., Diehl V., Gorgen H. et al. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J. Clin. Oncol. 2010. Vol. 28. No. 27. P. 4199-4206.
  39. Gallamini A., Hutchings M., Rigacci L. et al. Early interim 2- [18F] fluoro-2-depxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. J. Clin. Oncol. 2007. Vol. 25. No. 24. P. 3746-3752.
  40. Press O.W., LeBlanc M., Rimsza H. et al. Front-line treatment of Hodgkin’s lymphoma - A phase II trial of responce-adapted therapy of Stage III-IV Hodgkin’s lymphoma using early interim FDG-PET imaging: US Intergroup S0816. Hematol. Oncol. 2013. Suppl. 1. Abstr. 124.
  41. Girinsky T., van der Maazen R., Specht L. et al. Involve-node radiotherapy (INRT) in patients with early Hodgkin’s lymphoma: concepts and guidelines. Radiother. Oncol. 2006. Vol. 79. No. 3. P. 270-277.
  42. Raemaekers J.M., Andre M.P., Federico M. et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin’s lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J. Clin. Oncol. 2014. Vol. 32. No. 12. P. 1188-1194.
  43. Available from: http://en.ghsg.org/active-trials/articles/hd16-study.
  44. Radford J., Barrington S., Counsell N. et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin’s lymphoma and a “negative” PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID Trial. Blood. 2012. Vol. 120. Abstr. 547.
  45. Filippi A.R., Boticella A., Bello M. et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin’s lymphoma treated with combined modality therapy. Leuk. Lymph. 2013. Vol. 54. No. 6. P. 1183-1187.
  46. Gallamini A., Barrington S.F., Biggi A. et al. The predictive role of interim positron emission tomography for Hodgkin’s lymphoma treatment outcome in confirmed using the interpretation criteria of the Deauville fivepoint scale. Haematol. 2014. Vol. 99. No. 6. P. 1107-1113.
  47. Jahalom J., Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann. Oncol. 2002. Vol. 13. Suppl. 1. P. 79-83.
  48. Maraldo M.V., Brodin P., Aznar M.C. et al. Estimated risc of cardiovascular disease and secondari cancers with modern highly conformal radiotherapy for early stage mediastinal Hodgkin’s lymphoma. Ann. Oncol. 2013. Vol. 24. No. 8. P. 2113-2118.
  49. Ricardi U., Filippi A.R., Piva C., Franco P. The evolving role of radiotherapy in early stage Hodgkin’s lymphoma. Mediter. Hematol. Infect. 2014. Vol. 6. No. 1. DOI: 10.4084/MJHID.2014.035.
  50. Campbell B.A., Hornby C., Cunninghame J. Minimising critical organ irradiation in limited stage Hodgkin’s lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann. Oncol. 2012. Vol. 23. No. 50. P. 1259-1266.
  51. De Bruin M.L., Sparidans J., van’t Veer M.B. et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J. Clin. Oncol. 2009. Vol. 27. No. 26. P. 4239-4246.
  52. Maraldo M.V., Aznar M.C., Vogelius I.R. et al. Involved node radiation therapy: an effective alternative in earlystage Hodgkin’s lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 2013. Vol. 85. No. 4. P. 1057-1065.
  53. Engert A., Horning S.J. Hodgkin Lymphoma: a Comprehensive Update on Diagnostics and Clinics. Berlin - Heidelberg. 2011. 381 p.
  54. Younes A., Gopal A.K., Smith S.E. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012. Vol. 30. No. 18. P. 2183-2189.
  55. Deluca P., Jones D., Gahbauer R. et al. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT [report 83]. JICRU. 2010. Vol. 10. No. 1. P. 1-106.
  56. Specht L., Yahalom J., Illidge T. et al. ILROG. Modern radiation therapy for Hodgkin’s lymphoma: Field and dose guidelines from the International lymphoma radiation oncology group (ILROG). Int. J. Radiat. Biol. Phys. 2014. Vol. 89. No. 4. P. 854-862.
  57. Goda J.S., Massey C., Kuruvilla J. et al. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int. J. Radiat. Biol. Phys. 2012. Vol. 84. No. 3. P. 329-335.

For citation: Osovets S.V. Revisiting the Theory of Radiation Injury and Recovery. Medical Radiology and Radiation Safety. 2015;60(4):71-80. Russian.

PDF (RUS) Full-text article (in Russian)

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2940883
Today
Yesterday
This week
Last week
This month
Last month
For all time
2009
2306
18121
33458
39179
113593
2940883
Forecast today
3936

Your IP:216.73.216.100
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх